 | • レポートコード：MRC23Q36422 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、81ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の輸血依存性貧血治療市場について調査・分析し、世界の輸血依存性貧血治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（細胞治療、医薬品、その他）、用途別セグメント分析（病院、外来手術センター、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bluebird bio, Inc.、Novartis AG、Takeda Pharmaceuticals、Acceleron Pharma, Inc.、Celgene Corporationなどが含まれています。世界の輸血依存性貧血治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、輸血依存性貧血治療市場規模を推定する際に考慮しました。本レポートは、輸血依存性貧血治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、輸血依存性貧血治療に関するビジネス上の意思決定に役立てることを目的としています。 ・輸血依存性貧血治療市場の概要 - 輸血依存性貧血治療のタイプ別セグメント - 世界の輸血依存性貧血治療市場規模：タイプ別分析（細胞治療、医薬品、その他） - 輸血依存性貧血治療の用途別セグメント - 世界の輸血依存性貧血治療市場規模：用途別分析（病院、外来手術センター、その他） - 世界の輸血依存性貧血治療市場規模予測（2018年-2029年） ・輸血依存性貧血治療市場の成長トレンド - 輸血依存性貧血治療の地域別市場規模（2018年-2029年） - 輸血依存性貧血治療市場ダイナミクス - 輸血依存性貧血治療の業界動向 - 輸血依存性貧血治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：細胞治療、医薬品、その他 - 世界の輸血依存性貧血治療のタイプ別市場規模（2018年-2023年） - 世界の輸血依存性貧血治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、外来手術センター、その他 - 世界の輸血依存性貧血治療の用途別市場規模（2018年-2023年） - 世界の輸血依存性貧血治療の用途別市場規模（2024年-2029年） ・輸血依存性貧血治療の地域別市場規模 - 北米の輸血依存性貧血治療市場規模（2018年-2029年） - アメリカの輸血依存性貧血治療市場規模（2018年-2029年） - ヨーロッパの輸血依存性貧血治療市場規模（2018年-2029年） - アジア太平洋の輸血依存性貧血治療市場規模（2018年-2029年） - 中国の輸血依存性貧血治療市場規模（2018年-2029年） - 日本の輸血依存性貧血治療市場規模（2018年-2029年） - 韓国の輸血依存性貧血治療市場規模（2018年-2029年） - インドの輸血依存性貧血治療市場規模（2018年-2029年） - オーストラリアの輸血依存性貧血治療市場規模（2018年-2029年） - 中南米の輸血依存性貧血治療市場規模（2018年-2029年） - 中東・アフリカの輸血依存性貧血治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Bluebird bio, Inc.、Novartis AG、Takeda Pharmaceuticals、Acceleron Pharma, Inc.、Celgene Corporation ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Transfusion-dependent Anemia Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Transfusion-dependent Anemia Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Transfusion-dependent Anemia Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Transfusion-dependent Anemia Treatment in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Transfusion-dependent Anemia Treatment include Bluebird bio, Inc., Novartis AG, Takeda Pharmaceuticals, Acceleron Pharma, Inc. and Celgene Corporation, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transfusion-dependent Anemia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transfusion-dependent Anemia Treatment.
The Transfusion-dependent Anemia Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Transfusion-dependent Anemia Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transfusion-dependent Anemia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bluebird bio, Inc.
Novartis AG
Takeda Pharmaceuticals
Acceleron Pharma, Inc.
Celgene Corporation
Segment by Type
Cell Therapy
Medication
Others
Segment by Application
Hospital
Ambulatory Surgery Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transfusion-dependent Anemia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transfusion-dependent Anemia Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Cell Therapy
1.2.3 Medication
1.2.4 Others
1.3 Market by Application
1.3.1 Global Transfusion-dependent Anemia Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transfusion-dependent Anemia Treatment Market Perspective (2018-2029)
2.2 Transfusion-dependent Anemia Treatment Growth Trends by Region
2.2.1 Global Transfusion-dependent Anemia Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Transfusion-dependent Anemia Treatment Historic Market Size by Region (2018-2023)
2.2.3 Transfusion-dependent Anemia Treatment Forecasted Market Size by Region (2024-2029)
2.3 Transfusion-dependent Anemia Treatment Market Dynamics
2.3.1 Transfusion-dependent Anemia Treatment Industry Trends
2.3.2 Transfusion-dependent Anemia Treatment Market Drivers
2.3.3 Transfusion-dependent Anemia Treatment Market Challenges
2.3.4 Transfusion-dependent Anemia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transfusion-dependent Anemia Treatment Players by Revenue
3.1.1 Global Top Transfusion-dependent Anemia Treatment Players by Revenue (2018-2023)
3.1.2 Global Transfusion-dependent Anemia Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Transfusion-dependent Anemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Transfusion-dependent Anemia Treatment Revenue
3.4 Global Transfusion-dependent Anemia Treatment Market Concentration Ratio
3.4.1 Global Transfusion-dependent Anemia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transfusion-dependent Anemia Treatment Revenue in 2022
3.5 Transfusion-dependent Anemia Treatment Key Players Head office and Area Served
3.6 Key Players Transfusion-dependent Anemia Treatment Product Solution and Service
3.7 Date of Enter into Transfusion-dependent Anemia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transfusion-dependent Anemia Treatment Breakdown Data by Type
4.1 Global Transfusion-dependent Anemia Treatment Historic Market Size by Type (2018-2023)
4.2 Global Transfusion-dependent Anemia Treatment Forecasted Market Size by Type (2024-2029)
5 Transfusion-dependent Anemia Treatment Breakdown Data by Application
5.1 Global Transfusion-dependent Anemia Treatment Historic Market Size by Application (2018-2023)
5.2 Global Transfusion-dependent Anemia Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Transfusion-dependent Anemia Treatment Market Size (2018-2029)
6.2 North America Transfusion-dependent Anemia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Transfusion-dependent Anemia Treatment Market Size by Country (2018-2023)
6.4 North America Transfusion-dependent Anemia Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transfusion-dependent Anemia Treatment Market Size (2018-2029)
7.2 Europe Transfusion-dependent Anemia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Transfusion-dependent Anemia Treatment Market Size by Country (2018-2023)
7.4 Europe Transfusion-dependent Anemia Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transfusion-dependent Anemia Treatment Market Size (2018-2029)
8.2 Asia-Pacific Transfusion-dependent Anemia Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Transfusion-dependent Anemia Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Transfusion-dependent Anemia Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transfusion-dependent Anemia Treatment Market Size (2018-2029)
9.2 Latin America Transfusion-dependent Anemia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Transfusion-dependent Anemia Treatment Market Size by Country (2018-2023)
9.4 Latin America Transfusion-dependent Anemia Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transfusion-dependent Anemia Treatment Market Size (2018-2029)
10.2 Middle East & Africa Transfusion-dependent Anemia Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Transfusion-dependent Anemia Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Transfusion-dependent Anemia Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bluebird bio, Inc.
11.1.1 Bluebird bio, Inc. Company Detail
11.1.2 Bluebird bio, Inc. Business Overview
11.1.3 Bluebird bio, Inc. Transfusion-dependent Anemia Treatment Introduction
11.1.4 Bluebird bio, Inc. Revenue in Transfusion-dependent Anemia Treatment Business (2018-2023)
11.1.5 Bluebird bio, Inc. Recent Development
11.2 Novartis AG
11.2.1 Novartis AG Company Detail
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Transfusion-dependent Anemia Treatment Introduction
11.2.4 Novartis AG Revenue in Transfusion-dependent Anemia Treatment Business (2018-2023)
11.2.5 Novartis AG Recent Development
11.3 Takeda Pharmaceuticals
11.3.1 Takeda Pharmaceuticals Company Detail
11.3.2 Takeda Pharmaceuticals Business Overview
11.3.3 Takeda Pharmaceuticals Transfusion-dependent Anemia Treatment Introduction
11.3.4 Takeda Pharmaceuticals Revenue in Transfusion-dependent Anemia Treatment Business (2018-2023)
11.3.5 Takeda Pharmaceuticals Recent Development
11.4 Acceleron Pharma, Inc.
11.4.1 Acceleron Pharma, Inc. Company Detail
11.4.2 Acceleron Pharma, Inc. Business Overview
11.4.3 Acceleron Pharma, Inc. Transfusion-dependent Anemia Treatment Introduction
11.4.4 Acceleron Pharma, Inc. Revenue in Transfusion-dependent Anemia Treatment Business (2018-2023)
11.4.5 Acceleron Pharma, Inc. Recent Development
11.5 Celgene Corporation
11.5.1 Celgene Corporation Company Detail
11.5.2 Celgene Corporation Business Overview
11.5.3 Celgene Corporation Transfusion-dependent Anemia Treatment Introduction
11.5.4 Celgene Corporation Revenue in Transfusion-dependent Anemia Treatment Business (2018-2023)
11.5.5 Celgene Corporation Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details